Metabolic biomarker for predicting hepatic fibrosis progress and application thereof

A set of metabolic biomarkers was screened through metabolomics and combined with nuclear magnetic resonance spectroscopy to solve the problem of screening for early liver fibrosis in MAFLD, achieving high accuracy and specific diagnosis and risk prediction.

CN119688762APending Publication Date: 2025-03-25ZHEJIANG UNIV OF TECH
0 Cites 0 Cited by

Patent Information

Application Number
CN202411846263.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-16
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

The prior art is difficult to effectively screen and diagnose early liver fibrosis in MAFLD. The traditional methods are costly, time-consuming, and lack biomarkers with high sensitivity and strong specificity.

Method used

A set of metabolic biomarkers, such as acetic acid, alanine, arginine, citric acid, glucose, glycerol, lysine, ornithine, pyruvate, succinic acid and tyrosine, was screened through metabolomics technology, and the concentrations of these markers were detected in combination with nuclear magnetic resonance spectroscopy to distinguish between normal populations and liver fibrotic populations.

Benefits of technology

It achieves high accuracy and specificity in early diagnosis, screening and risk prediction of liver fibrosis, simplifies sample pre-processing and detection operations, and improves the convenience and accuracy of detection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a metabolic biomarker for predicting the progress of hepatic fibrosis and application of the metabolic biomarker, a group of metabolic biomarkers with diagnostic value is screened out through a metabonomics method, and the metabolic biomarkers comprise acetic acid, alanine, arginine, citric acid, glucose, glycerol, lysine, ornithine, pyruvic acid, succinic acid and tyrosine. By using these biomarkers in combination, the accuracy and specificity of diagnosis can be further improved. A biological sample is collected from a tested object, the content of the biomarker is detected, and the content is compared with a preset threshold concentration for analysis, the detection means is nuclear magnetic resonance spectroscopy, and compared with the prior art, the sample pretreatment steps are simpler, the experiment operation is quicker, and the detection accuracy is higher. The problems that early hepatic fibrosis is not easy to perceive and a traditional diagnosis and treatment method is high in cost and long in consumed time are solved, and the accuracy of early hepatic fibrosis diagnosis is effectively improved.
Need to check novelty before this filing date? Find Prior Art